HK1183877A1 - Substituted pyridine compound - Google Patents

Substituted pyridine compound

Info

Publication number
HK1183877A1
HK1183877A1 HK13111517.6A HK13111517A HK1183877A1 HK 1183877 A1 HK1183877 A1 HK 1183877A1 HK 13111517 A HK13111517 A HK 13111517A HK 1183877 A1 HK1183877 A1 HK 1183877A1
Authority
HK
Hong Kong
Prior art keywords
substituted pyridine
pyridine compound
compound
substituted
pyridine
Prior art date
Application number
HK13111517.6A
Other languages
English (en)
Chinese (zh)
Inventor
Tsuyoshi Nakamura
Hidenori Namiki
Naoki Terasaka
Akiko Shima
Masahiko Hagihara
Noriaki Iwase
Katsunori Takata
Osamu Kikuchi
Kazunari Tsuboike
Hiroyuki Setoguchi
Kenji Yoneda
Hidetoshi Sunamoto
Koji Ito
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1183877A1 publication Critical patent/HK1183877A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK13111517.6A 2010-07-09 2013-10-11 Substituted pyridine compound HK1183877A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010156590 2010-07-09
PCT/JP2011/065651 WO2012005343A1 (ja) 2010-07-09 2011-07-08 置換ピリジン化合物

Publications (1)

Publication Number Publication Date
HK1183877A1 true HK1183877A1 (en) 2014-01-10

Family

ID=45441319

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111517.6A HK1183877A1 (en) 2010-07-09 2013-10-11 Substituted pyridine compound

Country Status (20)

Country Link
US (1) US9187450B2 (ko)
EP (1) EP2592076B1 (ko)
JP (1) JP5739426B2 (ko)
KR (1) KR101764458B1 (ko)
CN (1) CN103221405B (ko)
AU (1) AU2011274903B2 (ko)
BR (1) BR112013000389A2 (ko)
CA (1) CA2804924C (ko)
CO (1) CO6670582A2 (ko)
ES (1) ES2543176T3 (ko)
HK (1) HK1183877A1 (ko)
IL (1) IL223866A (ko)
MX (1) MX2013000359A (ko)
MY (1) MY158199A (ko)
NZ (1) NZ606100A (ko)
RU (1) RU2572606C2 (ko)
SG (1) SG186493A1 (ko)
TW (1) TWI506025B (ko)
WO (1) WO2012005343A1 (ko)
ZA (1) ZA201300155B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860601C (en) * 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
JP2017019724A (ja) * 2013-10-25 2017-01-26 第一三共株式会社 置換ピリジン化合物および他の医薬の組み合わせ
TWI634120B (zh) * 2013-12-13 2018-09-01 日商第一三共股份有限公司 ５－羥基－４－（三氟甲基）吡唑并吡啶衍生物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
AU3285499A (en) * 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6593333B1 (en) 1998-10-01 2003-07-15 Astrazeneca Ab Substituted anilino-quinazoline (or quinoline) compounds and use thereof
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
BRPI0519566A2 (pt) 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
BRPI0519602A2 (pt) * 2004-12-18 2009-02-25 Bayer Healthcare Ag derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
JP2010530416A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
ES2372012T3 (es) 2008-03-05 2012-01-12 Boehringer Ingelheim International Gmbh Derivados de piridina tricíclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparación.

Also Published As

Publication number Publication date
JPWO2012005343A1 (ja) 2013-09-05
BR112013000389A2 (pt) 2016-06-07
ZA201300155B (en) 2013-09-25
MY158199A (en) 2016-09-15
SG186493A1 (en) 2013-01-30
IL223866A (en) 2016-07-31
EP2592076A4 (en) 2013-10-16
WO2012005343A1 (ja) 2012-01-12
CO6670582A2 (es) 2013-05-15
US20130109653A1 (en) 2013-05-02
KR20130093068A (ko) 2013-08-21
ES2543176T3 (es) 2015-08-17
CA2804924C (en) 2016-06-28
US20140005143A2 (en) 2014-01-02
TW201206904A (en) 2012-02-16
RU2572606C2 (ru) 2016-01-20
AU2011274903A1 (en) 2013-02-14
EP2592076B1 (en) 2015-05-13
AU2011274903B2 (en) 2016-09-08
NZ606100A (en) 2014-08-29
US20140213549A9 (en) 2014-07-31
JP5739426B2 (ja) 2015-06-24
KR101764458B1 (ko) 2017-08-02
TWI506025B (zh) 2015-11-01
CN103221405B (zh) 2015-04-22
US9187450B2 (en) 2015-11-17
RU2013105475A (ru) 2014-08-20
CA2804924A1 (en) 2012-01-12
MX2013000359A (es) 2013-02-11
EP2592076A1 (en) 2013-05-15
CN103221405A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
HRP20181788T1 (hr) Supstituirani spojevi piridinon-piridinil
AP3607A (en) Substituted imidazopyridazines
HK1171452A1 (en) Substituted pyrrolidine-2-carboxamides -2-
EP2590647A4 (en) PRO-NEUROGENIC COMPOUNDS
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
HK1179964A1 (en) Anellated pyridine compounds
HK1188782A1 (en) Substituted sodium-1h-pyrazole-5-olate 1h--5-
HK1188597A1 (en) Continuous arycyclic compound
GB201002911D0 (en) Compound
GB201017315D0 (en) Compound
GB201007789D0 (en) Novel Compound
HK1183877A1 (en) Substituted pyridine compound
GB201007209D0 (en) Compound
GB201021228D0 (en) Compound
GB201015798D0 (en) Compound
GB201008820D0 (en) Compound
GB201005980D0 (en) Compound
GB201002810D0 (en) Novel compound
GB201003745D0 (en) Novel compounds ll

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190704